Several phosphodiesterase inhibitors have been reported to possess antiischaemic properties by improving myocardial oxygen demand/supply balance. Levosimendan is a new phosphodiesterase inhibitor with calcium-sensitizing properties. We investigated the functional and antiischaemic properties of levosimendan in isolated electrically-driven rabbit hearts (Langendorff, constant perfusion pressure: 70 cm H2O, Tyrode solution, Ca++ 1.8 mmol/l, 37 degrees, 200 beats/min.). Acute regional myocardial ischaemia was induced by ligature of a circumflex artery branch and quantified from epicardial NADH-fluorescence photography. RESULTS The left ventricular pressure was similarly enhanced by levosimendan 10(-7) M or 5 x 10(-6) M (+15%) (P < 0.05). The global coronary flow was increased more markedly by levosimendan 5 x 10(-6) M (+35-50%) compared to 10(-7) M (+25%) (P < 0.05). The relative coronary flow (= global coronary flow/pressure-rate-product) was significantly enhanced only by levosimendan 5 x 10(-6) M (+20-35%) (P < 0.05), but not by levosimendan 10(-7) M (+10-15%) (P > 0.05). Epicardial NADH-fluorescence area and intensity were significantly diminished by levosimendan (-20%) (P < 0.05), and there was no significant difference between myocardial ischaemia reduction by levosimendan 10(-7) M and 5 x 10(-6) M (P > 0.05). CONCLUSIONS Levosimendan is an inotrope with coronary dilator activity, showing antiischaemic effects in isolated rabbit hearts. These may be caused by (1) phosphodiesterase-inhibition and improvement of myocardial perfusion and/or (2) by oxygen-sparing effects, related to calcium sensitization of myofilaments, particularly at lower concentrations associated with a lower coronary dilator activity.